首页> 外文期刊>Bone marrow transplantation >Assessing the efficacy of an ambulatory peripheral blood hematopoietic stem cell transplant program using reduced intensity conditioning in a low-middle-income country
【24h】

Assessing the efficacy of an ambulatory peripheral blood hematopoietic stem cell transplant program using reduced intensity conditioning in a low-middle-income country

机译:在低中原国家利用减少强度调节,评估动态外周血造血干细胞移植计划的疗效

获取原文
获取原文并翻译 | 示例
           

摘要

Efficacy of an ambulatory hematopoietic stem cell transplant (HSCT) program with a reduced intensity conditioning regimen (RIC) in malignant hematological diseases was assessed. We analyzed 217 patients who underwent HSCT from August 2013 to July 2017. There were 78 (35.9%) HLA-identical, 56 (25.8%) haploidentical, and 83 (38.2%) autologous transplants. Two-year transplant-related mortality (TRM) for HLA-identical, haploidentical, and auto grafts were 20%, 25%, and 2.5%; relapse/progression was 44%, 60%, and 55%; overall survival (OS) was 61%, 44.8%, and 78.0%; and disease-free survival (DFS) was 36.8%, 26.5%, and 43.5%, respectively. Factors associated with a high risk of TRM were male sex (HR = 2.62, P = 0.031), fever and neutropenia (HR = 3.30, P = 0.023), and cell dose < 5 x 10(6) CD34 +/kg (HR = 4.24, P = 0.001); cGVHD was a protective factor for TRM (HR = 0.29, P = 0.022). Transfusion was associated with increased risk of relapse/progression in univariate and multivariate analysis (HR = 3.10, P = 0.001 and HR = 3.30, P = 0.004); cGVHD was a protective factor (HR = 0.18, P = 0.001 and HR = 0.17, P = 0.002). In a multivariate analysis for allo-HSCT, infections were associated with high risk of mortality (HR = 3.90, P = 0.016) and transfusion with reduced DFS (HR = 2.76, P = 0.029); for haplo-HSCT, CD34 + < 5 x 10(6)/kg was a risk factor for mortality and lower DFS (HR = 5.41, P = 0.001 and HR = 3.93, P = 0.001). Outcomes of our RIC-based outpatient transplant program are comparable to excellence centers in high-income countries.
机译:评估了具有降低的强度调理方案(RIC)在恶性血液天动疾病中具有降低的强度调理方案(RIC)的动态造血干细胞移植(HSCT)程序的疗效。我们分析了217名从2013年8月到2017年7月接受了HSCT的患者。78例(35.9%)HLA相同,56(25.8%)HAPLoIdentical和83(38.2%)的自体移植物。 HLA相同,寄和寄生和自动移植物的两年移植相关死亡率(TRM)为20%,25%和2.5%;复发/进展为44%,60%和55%;总生存期(OS)为61%,44.8%和78.0%;无病生存期(DFS)分别为36.8%,26.5%和43.5%。具有高风险的因素是男性性别(HR = 2.62,P = 0.031),发热和中病症(HR = 3.30,P = 0.023)和细胞剂量<5×10(6)CD34 + / kg(HR = 4.24,p = 0.001); CGVHD是TRM的保护因子(HR = 0.29,P = 0.022)。输血与单变量和多变量分析中复发/进展的风险增加有关(HR = 3.10,P = 0.001和HR = 3.30,P = 0.004); CGVHD是一种保护因子(HR = 0.18,p = 0.001和Hr = 0.17,p = 0.002)。在Allo-Hsct的多变量分析中,感染与高死亡风险有关(HR = 3.90,P = 0.016),并用减少的DFS输送(HR = 2.76,P = 0.029);对于HAPLO-HSCT,CD34 + <5×10(6)/ kg是死亡率和低DF的危险因素(HR = 5.41,P = 0.001和HR = 3.93,P = 0.001)。我们RIC的门诊移植计划的结果与高收入国家的卓越中心相当。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号